Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome
Yıl: 2021 Cilt: 28 Sayı: 6 Sayfa Aralığı: 1260 - 1262 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2020.04.416 İndeks Tarihi: 26-11-2021
Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome
Öz: Ovarian hyperstimulation syndrome (OHSS) caused by controlled ovarian hyperstimulation ,although usually regressingspontaneously, may occasionally occur with clomiphene citrate, typically with gonadotropin, which sometimes results in seriouscomplications. 25-year-old patient was followed up in our hospital due to OHSS. Since our patient was Clomiphene Citrate (CC)resistant Polycystic ovary syndrome (PCOS), follitropin alpha was started. Firstly, treatment started from 75 IU rFSH. Increasedto 150 IU on day 15, if no improvement in the ovaries. Due to the development of two 18 mm follicles on the 21st day and theE2 value being 773 pg/mL, human chorionic gonadotropin (hCG) was applied and insemination was performed. Patients with CCresistant PCOS represent a challenge for reproductive medicine. We propose a calculated low-dose stimulation strategy with step up according to ovarian response in gonadotropins protocols. If the treatment period is extended and the dose is increased; Even ifthe follow-up values are normal, the patient should be closely monitored to avoid OHSS.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
- 1. Azziz R,Woods K, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9.
- 2. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv Clin Exp Med 2017;26:359-67.
- 3. Brown J, Farquhar C, Beck J, et al. Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev 2005;1:CD002249.
- 4. Neulen J, Yan Z, Raczek S, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995;80:1967-7.
- 5. Kalem M, Kalem Z, & Gurgan T. Problems and Complications During the Treatment of Infertility in Women with Polycystic Ovary Syndrome. Gynecol Obstet Reprod Med 2016;22:113-24.
- 6. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproduction technologies: prevention and treatment. Fertil Steril 1992;58:249- 61.
- 7. Bergh PA, Navot D. Ovarian hyperstimulation syndrome: A review of pathophysiology. J Assist Reprod Genet 1992;9:429-38.
- 8. Whelan JG, 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73:883- 96.
- 9. Polishuk WZ, Schenker JG. Ovarian overstimulation syndrome. Fertil Steril 1969;20:443-50.
- 10. Rizk B, Aboulghar M, Smitz J, et al. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997;3:255-66.
- 11. Delbaere A, Bergmann PJM, Gervy-Decoster C, et al. Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome. Hum Reprod 1997;12:236-40.
- 12. Abd Elgafor I. Efficacy of combined metforminletrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome. Arch Gynecol Obstet 2013;288:119-23.
- 13. Cupisti S. Komplikation bei Ovulations induktion. Das ovarielle Überstimulationssyndrom. Geburtshilfe Frauenheilkd 2012;72:798-801
- 14. Yildizhan R, Adali E, Kolusari A, et al.Ovarian Hyperstimulation Syndrome with pleural effusion: A case report. Cases J 2008;1:323
- 15. Gulerman C, Yilmaz, N, Sargin Oruc, et al. Coasting Versus GnRH Antagonist Salvage for the Prevention of Ovarian Hyperstimulation Syndrome. Gynecol Obstet Reprod Med 2016;19:176-9.
| APA | Ege S (2021). Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome. , 1260 - 1262. 10.5455/annalsmedres.2020.04.416 |
| Chicago | Ege Serhat Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome. (2021): 1260 - 1262. 10.5455/annalsmedres.2020.04.416 |
| MLA | Ege Serhat Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome. , 2021, ss.1260 - 1262. 10.5455/annalsmedres.2020.04.416 |
| AMA | Ege S Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome. . 2021; 1260 - 1262. 10.5455/annalsmedres.2020.04.416 |
| Vancouver | Ege S Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome. . 2021; 1260 - 1262. 10.5455/annalsmedres.2020.04.416 |
| IEEE | Ege S "Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome." , ss.1260 - 1262, 2021. 10.5455/annalsmedres.2020.04.416 |
| ISNAD | Ege, Serhat. "Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome". (2021), 1260-1262. https://doi.org/10.5455/annalsmedres.2020.04.416 |
| APA | Ege S (2021). Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome. Annals of Medical Research, 28(6), 1260 - 1262. 10.5455/annalsmedres.2020.04.416 |
| Chicago | Ege Serhat Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome. Annals of Medical Research 28, no.6 (2021): 1260 - 1262. 10.5455/annalsmedres.2020.04.416 |
| MLA | Ege Serhat Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome. Annals of Medical Research, vol.28, no.6, 2021, ss.1260 - 1262. 10.5455/annalsmedres.2020.04.416 |
| AMA | Ege S Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome. Annals of Medical Research. 2021; 28(6): 1260 - 1262. 10.5455/annalsmedres.2020.04.416 |
| Vancouver | Ege S Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome. Annals of Medical Research. 2021; 28(6): 1260 - 1262. 10.5455/annalsmedres.2020.04.416 |
| IEEE | Ege S "Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome." Annals of Medical Research, 28, ss.1260 - 1262, 2021. 10.5455/annalsmedres.2020.04.416 |
| ISNAD | Ege, Serhat. "Controlled ovarian hyperstimulation with gonadotropinsfor Clomiphene Citrate resistant Polycysticovary syndrome leads to a higher risk of ovarianhyperstimulation syndrome". Annals of Medical Research 28/6 (2021), 1260-1262. https://doi.org/10.5455/annalsmedres.2020.04.416 |
